Page last updated: 2024-11-07
prednisone and Dysautonomia
prednisone has been researched along with Dysautonomia in 1 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Patients with orthostatic intolerance, anhidrosis, constipation, urinary dysfunction, sicca syndrome and pupillary dysfunction had higher antibody titers than subjects that did not (P<0." | 1.35 | Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. ( Freeman, R; Gibbons, CH, 2009) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Gibbons, CH | 1 |
| Freeman, R | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.[NCT01522235] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2012-02-29 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Systolic Blood Pressure During 60° Tilt (ΔSBP)
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. (NCT01522235)
Timeframe: Baseline and 6 weeks
| Intervention | mmHg (Mean) |
|---|
| IVIg Group | 42.5 |
| Placebo Group | -12.3 |
Change in Systolic Blood Pressure During 60° Tilt (ΔSBP)
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). (NCT01522235)
Timeframe: 6 weeks and 12 weeks
| Intervention | mmHg (Mean) |
|---|
| IVIG Group | -26 |
| Placebo Group | -7.6 |
Composite Autonomic Severity Score (CASS) Questionnaire.
"To determine the change in autonomic symptoms (measured by the composite autonomic severity score [CASS]) measured at baseline and 6 weeks in individuals receiving IVIg.~Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|
| IVIg Group | 0.5 |
| Placebo Group | 0 |
Composite Autonomic Symptom Score [COMPASS] Questionnaire
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score [COMPASS] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|
| IVIg Group | -5 |
| Placebo Group | -0.33 |
EuroQol [EQ-5D] Questionnaire.
"To determine the change in quality of life (measured by the EuroQol [EQ-5D]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|
| IVIg Group | 15 |
| Placebo Group | 9.3 |
Orthostatic Hypotension Symptom Assessment Questionnaire
"To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60.~Higher values represent worse outcome. We are reporting the total score." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|
| Group A | -9 |
| Group B | 12 |
Other Studies
1 other study available for prednisone and Dysautonomia